Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 NCT04426695

casirivimab/imdevimab (Ronapreve) (n=912) vs. placebo (n=452)

randomized controlled trial   some concerns about risk of bias

Studied treatment

REGEN-COV Casirivimab and imdevimab
2.4 g or 8.0 gREGEN-COV (1.2 g casirivimab and1.2 g imdevimab)

Control treatment

Placebo
Single intravenous dose.

3 arms ratio 1:1:1 : 2.4 g REGEN-COV (1.2 g casirivimab and1.2 g imdevimab), 8.0 g REGEN-COV (4.0 g casirivimab and 4.0 g imdevimab), or placebo as a single intravenous dose. Standard-of-care treatments for Covid-19, per the investigator, were permitted.

Patients

COVID-19 mild to moderate

Method

Double-blind.

103 sites in the United States, Brazil, Chile, Mexico, Moldova, and Romania

Primary endpoints were tested hierarchically.

Remark

*Warning! The spread of new Sars-Cov2 variants is constantly evolving, this study was performed in a different viral context than today, its results should be interpreted accordingly.* Trial was stopped earlier than planned (due to low enrollment prior to the surge associated with the Delta variant).